Alanine aminotransferase (ALT) activity is the most frequently relied upon reference standard for monitoring liver injury in humans and nonclinical species. However, limitations of ALT include a lack of specificity for diagnosing liver injury (e.g., present in muscle and the gastrointestinal tract), its inability to monitor certain types of hepatic injury (e.g., biliary injury), and ambiguity with respect to interpretation of modest or transient elevations (< 3× upper limit of normal). As an initial step to both understand and qualify additional biomarkers of hepatotoxicity that may add value to ALT, three novel candidates have been evaluated in 34 acute toxicity rat studies: (1) alpha-glutathione S-transferase (GSTA), (2) arginase 1 (ARG1), and (3) 4-hydroxyphenylpyruvate dioxygenase (HPD). The performance of each biomarker was assessed for its diagnostic ability to accurately detect hepatocellular injury (i.e., microscopic histopathology), singularly or in combination with ALT. All three biomarkers, either alone or in combination with ALT, improved specificity when compared with ALT alone. Hepatocellular necrosis and/or degeneration were detected by all three biomarkers in the majority of animals. ARG1 and HPD were also sensitive in detecting single-cell necrosis in the absence of more extensive hepatocellular necrosis/degeneration. ARG1 showed the best sensitivity for detecting biliary injury with or without ALT. All the biomarkers were able to detect biliary injury with single-cell necrosis. Taken together, these novel liver toxicity biomarkers, GSTA, ARG1, and HPD, add value (both enhanced specificity and sensitivity) to the measurement of ALT alone for monitoring drug-induced liver injury in rat.
The identification, evaluation, and qualification of novel biomarkers for improved understanding of drug-induced liver injury in nonclinical and clinical studies during drug development remain an important goal. Despite the existence of relatively well-characterized enzymes that indicate liver injury, namely alanine aminotransferase (ALT) and aspartate aminotransferase (AST), there remains a need to integrate additional biomarkers to further inform and improve risk assessment throughout the drug development cycle. Limitations of measuring ALT alone include the lack of specificity for liver injury and its inability to monitor more subtle hepatocellular lesions or to detect biliary injury. The sensitivity of ALT to accurately diagnose mild to moderate hepatocellular injury is not at issue but rather, the problem is the inability of ALT to diagnose the severity of injury or prognosis of liver failure in the clinic (Abraham and Furth, 1995; Aithal and Day, 1999; Nathwani et al., 2005a,b; Pratt and Kaplan, 2000; Watkins, 2005; Watkins et al., 2006) . Similar discordance between traditional hepatocellular and biliary (e.g., total bilirubin) biomarkers and liver histopathology is observed in preclinical toxicity studies (Ennulat et al., 2010; Solter, 2005; Travlos et al., 1996; Wang et al., 1997) . Addressing these deficiencies, both nonclinically and clinically, will require additional wellcharacterized translational biomarkers. To demonstrate an improved diagnostic capability over ALT alone for detecting complex manifestations of liver injury, severity, and prognosis, any such novel biomarker should first be evaluated in a nonclinical animal model where comprehensive evaluation of outcome is possible. New biomarkers must be at least as sensitive as ALT and more specific or discriminating to add functional value. Such characterizations are best determined within a qualification paradigm that includes collaboration among the pharmaceutical industry, academia, and regulatory authorities .
The objective of this evaluation was to characterize the performance of three novel sera/plasma biomarkers to diagnose drug-induced hepatocellular and biliary injury. Further, they were evaluated for their ability to distinguish drug-induced liver injury from muscle or gastrointestinal (GI) injury and from other liver findings of less concern (e.g., hypertrophy) in rat toxicity models. Alpha-glutathione S-transferase (GSTA), arginase 1 (ARG1), and 4-hydroxyphenylpyruvate dioxygenase (HPD) were selected as novel biomarker candidates of liver injury based on specific tissue distribution, response to hepatocellular injury in serological samples, and likelihood of successful clinical translation (Amacher, 2002; Ozer et al., 2008) . "Fit-for-Purpose" ELISAs for these biomarkers have been developed and validated (Ikemoto et al., 1990 (Ikemoto et al., , 1993 Shaw, 2005) . In this publication, performance of these biomarkers has been assessed over a number of acute toxicity rat studies to compare specificity and sensitivity relative to ALT and to identify unique value added.
GSTA (EC 2.5.1.18) is a member of a complex family of multifunctional proteins primarily serving as phase II detoxification enzymes of xenobiotics. GSTA is a cytoplasmic protein comprising 5-10% of the soluble hepatic protein (Awasthi et al., 1994) . In humans, the alpha class of glutathione S-transferase accounts for up to 90% of all glutathione S-transferase in the liver, and there are at least five known subtypes clustered on chromosome 6 (Mulder et al., 1999) . In rats, there are three known and three predicted alpha protein subtypes, all with comparable expression levels in the liver. Both humans and rats show substantial GSTA expression in the kidney as well. Immunohistochemical (IHC) localization of GSTA in human tissues shows strong staining in the cytoplasm and nuclei of hepatocytes, in the proximal convoluted tubules of kidney, and in the adrenals, testis, and stomach (Campbell et al., 1991; Shaw, 2005) . Expression of GSTA in human liver is throughout the centrilobular region (Abei et al., 1989) .
Arginase (EC 3.5.3 .1) catalyzes the hydrolysis of arginine to ornithine and urea. It has a critical function in the mammalian liver as the final enzyme in the urea cycle responsible for the disposal of ammonia from protein catabolism. Arginase is also expressed at a substantially lower lever in various extrahepatic tissues and may play a role in regulating arginine levels and in providing ornithine for biosynthetic reactions that generate various critical intermediary metabolites such as glutamate, glutamine, gammaaminobutyric acid, agmatine, polyamines, creatine, proline, and nitric oxide. Two isoforms of arginase are known, ARG1 and ARG2. ARG1 is highly abundant in liver cytosol and is reported to be expressed at low levels in erythrocytes in humans and primates (Barksdale et al., 2004; Ochoa et al., 2001) . ARG2 is in the mitochondrial matrix with a low level of expression and a wide tissue distribution. Thus, monitoring the liver-specific isoform, ARG1, in serological samples should help to diagnose liver injury more specifically. IHC localization of ARG1 in rat liver shows the most intense staining around the portal vein, decreasing gradually toward the central vein. Parenchymal cells are positive for ARG1 staining, whereas Kupffer, endothelial, and bile duct (BD) cells are negative (Miyanaka et al., 1998) .
HPD (EC 1.13.11.27) , also known as F-antigen (F-ag), is an enzyme involved in tyrosine catabolism converting 4-hydroxyphenylpyruvate to homogentisate in a complex reaction involving decarboxylation, oxidation, and rearrangement. IHC localization of HPD protein and in situ hybridization of mRNA show a uniform distribution throughout the liver with strong expression in hepatocytes (Neve et al., 2003) . HPD is also expressed in the kidney epithelial cells of the proximal and distal tubules and in the loop of Henle. It is associated with the membranes of the endoplasmic reticulum and of the Golgi apparatus and transport vesicles (Hummel et al., 1992; Neve et al., 2003) .
The evaluation conducted on these three novel biomarkers involved assaying samples from 34 acute toxicity rat studies to address potential claims of equivalent or superior sensitivity in detecting hepatocellular and biliary injury, and claims of superior specificity in discriminating liver changes of less concern (hepatocellular hypertrophy) or injury to nonliver tissues such as cardiac/skeletal muscle or the GI tract. Biomarker performance was benchmarked against histopathological findings. Each biomarker was assessed alone or in combination with ALT. The manner in which the data were collected and analyzed could support a biomarker qualification submission to regulatory agencies, resulting in endorsement of these novel safety biomarkers for specific context of use claims (Goodsaid et al., 2010; Sistare et al., 2010) .
MATERIALS AND METHODS

Animals
Sprague Dawley, strain Crl:CD(SD), or Wistar, strain Crl:WI(HAN), rats were obtained from Charles River Laboratories (Raleigh, NC) for studies conducted in United States. For studies conducted in Japan, Sprague Dawley strain Crl:CD(SD) came from Charles River Laboratories Japan Inc., (Ishioka, Ibaraki, Japan) or Wistar strain BrlHan:WIST@Jc1(GALAS) was obtained from CLEA Japan Inc., (Fuji, Shizuoka, Japan). Animals were 6-10 weeks of age, weighing 120-425 grams. The rats were housed individually in wire mesh cages (at 18°C-26°C, relative humidity of 50 ± 20% on a 12-h light/12-h dark cycle), fed PMI Certified Rodent Diet (SD-restricted [fed 16-22 g shortly after dosing 1× per day] Wistar ad libitum). Animals were acclimated for at least 4 days prior to randomization into treatment groups. All animal husbandry and experimental procedures were in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, 1996) and were approved by the Institutional Animal Care and Use Committee of the facility in which the studies were conducted.
Study Samples
Test articles (n = 31) were selected based upon the type of end organ injury expected to occur from previous internal or published studies. The studies conducted were either routine exploratory toxicity studies of internal development compounds or biomarker studies using known compounds documented to elicit specific types of target organ injury. Dose selection for biomarker studies was based on either published or internal data. Doses were targeted to cause either no injury or target tissue injury without morbidity. Test articles were either obtained from Sigma-Aldrich (St Louis, MO) or provided by the sponsor. Dose formulations were prepared at a frequency dependent upon the stability of control and test article. Dose concentrations were not adjusted for purity.
General Study Design
Treatments (generally three or four dose groups per study) were administered to male or female rats (n = 4-12 per dose group) once daily for 1-14 days by oral gavage or ip injection. Rats were sacrificed by exsanguination under isoflurane anesthesia following an overnight fast prior to scheduled necropsy dates (24 h post last dose). Blood was collected at necropsy via vena cava in serum separator tubes for the measurement of clinical chemistry parameters. Clinical chemistry parameters including serum ALT, AST, total bilirubin, alkaline phosphatase (ALP), calcium, sodium, potassium, chloride, total protein, albumin/globulin ratio, glucose, cholesterol, triglycerides, urea nitrogen, creatinine, globulin, albumin, and creatine kinase were measured on a Roche Modular System using specific commercial assays (Bergmeyer et al., 1986; Tietz, 1995) . EDTA plasma samples were also collected from the majority of studies for biomarker analyses.
In general, for purpose-driven biomarker studies, the liver, kidney, heart, quadriceps muscle, and less frequently, soleus muscle were collected at necropsy for histomorphological examination. For routine exploratory toxicity studies on development compounds, additional tissues were evaluated. Tissues were fixed in 10% neutral buffered formalin, trimmed, processed to paraffin sections, and stained with hematoxylin and eosin. Livers from control, high-dose animals, and organs with test article-related hepatocellular or biliary changes from lower dose groups were examined microscopically by a Merck pathologist, and an informal peer review was performed according to routine laboratory work practice. Histopathology was assessed with knowledge of treatment groups but without knowledge of clinical chemistry or biomarker data. A severity score grading scale of 0 to 5 was employed to grade pathological lesions: 0 (no observable pathology), 1 (very slight), 2 (slight), 3 (moderate), 4 (marked), and 5 (severe). Diagnoses for individual animals were grouped into composite categories for statistical analysis: (1) degeneration and necrosis composite, (2) BD necrosis, BD hyperplasia, common BD vacuolation composite, (3) singlecell necrosis (SCN) alone, or (4) a composite of SCN and BD necrosis and/or hyperplasia. The composite score for an individual animal was derived from the highest pathology score of the diagnoses comprising a given composite.
For the purposes of biomarker evaluation, histopathology diagnoses in the liver were classified using the best practices as put forth by the Critical Path Institute's (C-PATH) Predictive Safety Testing Consortium (PSTC) Hepatotoxicity Working Group. This lexicon is an agreed upon set of terms intended to standardize histopathology diagnoses for the purposes of cross-site biomarker qualification.
ELISA
GSTA. GSTA levels in sera or plasma were measured using an assay developed by MesoScale Discovery (MSD). This ELISA detects all GSTA subtypes. The assay was preformed as described by MSD. Briefly, plates were blocked with MSD Blocker B, 0.5% in PBS for 1 h. Sera or plasma samples were diluted fivefold, and an eight-point calibration curve was prepared in MSD Diluent buffer 31, aliquoted into wells, and incubated for 2 h. A detection antibody to GSTA labeled with an electrochemiluminescent compound, MSD SULFO-TAG, was added to wells and incubated for 2 h. Plates were filled with MSD Read buffer and loaded into an MSD SECTOR instrument for analysis. The labeled detection antibody emits light when a voltage is applied to the plate electrodes, and a quantitative measure of GSTA in the sample was calculated using the generated standard curve on the plate. For protein quantification, standard curves were generated using a recombinant rat YaYc GST protein calibrator included with the commercial assay. The limits of quantification (LOQ) (defined as calibrator recovery between 80-120% and %CV values less than 25%) were determined to be 0.12 to 125 ng/ ml or 0.61 to 625 ng/ml adjusted for dilution factor. ARG1. ARG1 levels were detected with the use of a sandwich ELISA developed by Yamasa corporation (Cat no. 80025, HRP-labeled Monoclonal Antibody to Arginase 2C6; Cat no. 07899 Monoclonal Antibody to Human Liver-type Arginase 6G3; Cat no. 80024 Standard set for ARG EIA) (Ikemoto et al., 1989 (Ikemoto et al., , 1990 (Ikemoto et al., , 1993 . Procedure was performed according to the manufacturer's instructions. Plasma or sera samples were diluted fivefold in recommensded dilution buffer, and concentration in samples was calculated using the generated standard curve on the plate. For protein quantification, standard curves were generated using a recombinant human type 1 ARG protein calibrator included with the commercial assay. The LOQ (defined as calibrator recovery between 80-120% and %CV values less than 25%) were determined to be 1.97 to 106.6 ng/ml or 9.85 to 533 ng/ml adjusted for dilution factor.
HPD. The HPD sandwich ELISA was developed internally using custom antibodies directed against select epitopes on the HPD protein. The coating antibody was derived from the HPD sequence MTTYSNKGPKPERGRFLHFHS (a.a. position 1-21) (called P1), and detection antibody was derived from two HPD sequences RERGAKIVREPWVEEDKFGKVKF (a.a. position 111-133) (called P3) and NFNSLFFKAFEEEQALRGN (a.a. position 363-380) (called P4). Antibodies were generated at SDIX Strategic BioSolutions, Delaware. Antisera were raised in rabbits and guinea pigs, and sera were tested using an ELISA with the peptides at SDIX for determination of antibody titer. All positive sera were immuno-affinity purified using the peptides above resulting in purified antibodies against HPD.
An ELISA was developed and optimized using HPD P1 for coating and HPD P3 and P4 as detection antibody (biotinylated and column purified using a kit from Thermo Scientific). Briefly, the assay was performed using microtiter 96-well plates coated with capture antibody at 2 μg/ml in 1× PBS. Plates were incubated overnight at 4°C followed by blocking with 1% bovine serum albumin (BSA) in Protein Free Tween-20 (PFT20) diluent. Study samples were diluted into 1% BSA in PFT20 diluent at 1:25 and assayed in duplicate. Samples were incubated on a plate shaker (100-150 rpm) at room temperature for 1½ h and washed prior to addition of the secondary biotinylated antibody (3 μg/ml in 1% BSA in PFT20 diluent). A tetramethyl benzidine reagent was then added, and optical density was measured spectrophotometrically at 450 nm. The concentration of HPD in the sample was calculated using a calibrator generated by diluting rat liver injury-positive pool plasma in 1% BSA in PFT20 diluent. The concentration of the HPD analyte in this positive pool was determined using a mass spectrometry approach utilizing internally labeled standard peptides. The LOQ (defined as calibrator recovery between 80-120% and %CV values less than 25%) were determined to be 39.1 to 2500 ng/ml adjusted for dilution factor.
Although the assay readily recognized the analyte in pools generated from animals with liver histopathology, the assay had a high background level that could not be minimized using various blockers and buffers. Optimal dilution of the samples for this assay was determined to be 1:25, a dilution that yielded the highest dynamic range between control (untreated) animal pools and liver injury sample pools. Relatively high background and undetectable analyte in control were factors that did not have a substantial impact on the performance of HPD to detect liver injury. Data analysis. Liver positive samples included histopathology findings of hepatocellular necrosis, degeneration, regeneration, SCN, vacuolation, and biliary lesions including BD necrosis, BD hyperplasia, and common BD vacuolation. Samples which had only hepatocellular hypertrophy were not considered to have liver injury. All histopathology diagnoses from muscle types (quadriceps, soleus, and heart) were grouped into one muscle bin for purposes of specificity evaluation. All histopathology findings in the small intestine, large intestine, and stomach were grouped into a common GI bin. Early sacrifice animals with liver findings were excluded when evidence of multisystem organ failure was noted.
Sera or plasma samples with any grade of hemolysis were excluded, as were any sera/plasma sample from animals with underlying pyelonephritis. Only samples with data available for all four markers (ALT, GSTA, ARG1, and HPD) were included in the analysis. For primary histopathology classification, samples were first considered for the target organ toxicity known to be associated with the administered compound. When there were two injured organs (e.g., histopathological changes in both liver and muscle), positive liver histopathology findings for degeneration/necrosis, SCN, or biliary injury took precedence over findings for the other affected organs. In animals with multiple liver histopathology findings, hepatocellular degeneration/necrosis took precedence over all NOVEL DRUG-INDUCED LIVER INJURY BIOMARKERS other liver findings, and hepatocellular SCN took precedence over biliary injury (BD necrosis, hyperplasia, common BD vacuolation) . Some animals with more than one finding were given their own class for the purpose of statistical analysis (e.g., SCN and biliary injury). This priority ranking is needed to evaluate the sensitivity of a candidate biomarker's ability to diagnose various findings. Samples were placed in the liver hypertrophy or vacuolation classes when these findings were present in the absence of any other target organ toxicity.
Values for each of the markers were analyzed on the log (base 2) scale. Values below the LOQ were replaced by the LOQ/2. All values were normalized by subtracting the mean of the log (base 2) concurrent control values.
Data from eight studies expected to yield hepatocellular injury (carbon tetrachloride, CCl 4 [n = two studies], bromobenzene [n = two studies], acetaminophen [n = two studies], furan, and thioacetamide) were used to fit a linear logistic model (Harrell, 2001) for each marker individually and to fit each candidate marker together with ALT. The diagnostic scores (i.e., predicted values) from these models were used to summarize the evidence for liver injury that each marker gives alone or in combination with ALT. Net reclassification rate, mean improved sensitivity, and mean improved specificity were adapted from Pencina et al. (2008) . Receiver operating characteristic curves were calculated using the methodology of Sing et al. (2005) .
RESULTS
Tissue Distribution of Biomarkers and Histological Findings of Samples
In order to identify novel hepatotoxicity biomarkers, an internal transcriptional whole body atlas for rat consisting of over 50 tissues was queried for the most abundantly expressed mRNAs in liver. ARG1, GSTA, and HPD all showed substantial liver specificity relative to all other tissues surveyed in the atlas (data not shown). Of these candidates, ARG1 showed the most specific expression to liver, whereas GSTA and HPD were also present at high levels in kidney. To confirm the relative abundance of protein levels for GSTA, ARG1, and HPD, tissue homogenates from male and female rats were pooled and assayed (Table 1) . Relative quantification of protein concentrations was based on the quadriceps. Of the tissue pools examined, ARG1 is approximately 300× more abundant in liver than in the next most abundantly expressing tissue, lung. GSTA and HPD both showed high expression in kidney and liver, with GSTA equally expressed in both and HPD with 4× higher expression in liver than in kidney.
To evaluate novel biomarker performance relative to ALT, selected purpose-driven and exploratory studies needed to have at least one dose group with increased ALT levels either in the presence or in the absence of liver injury (with the exception of the kidney injury studies). Model compounds for conducting biomarker studies and internal development studies were selected based on a diverse manifestation of liver injury, benign liver findings, and other target organ injury (Table 2) . Histopathological categories included findings where improved specificity or sensitivity could be evaluated. Studies with liver (N = 18) histopathology findings of most concern in drug development, namely necrosis and degeneration, were selected for initial evaluation. Further, liver injury was subdivided into hepatocellular or biliary injury depending on cell type and location where histopathology was observed. Liver injury ranged from none to moderate, often with multiple concurrent morphologic diagnoses. Specificity studies (N = 16) were defined as presenting with treatment-related increases in ALT in the absence of histopathological findings in liver or with histomorphological findings in the liver of lesser concern (e.g., hypertrophy). Kidney injury studies were included to assess the specificity of GSTA and HPD because of the relatively high abundance of these proteins in the kidney.
Standard serum clinical chemistry including AST, ALP, and total bilirubin was measured in most of the studies along with ALT. Although each of these analytes, except ALT, was not directly compared with GSTA, ARG1 and HPD, a summary of their performance is shown in Table 2 . Detailed summary statistics on all biomarkers such as average values, standard deviations, and percent change over controls for each dose group are included in Supplementary table 1. ALP is increased in 10 of the studies with mild to severe liver injury and in 4 specificity studies. Due to the high variability and the fact that only two samples from the seven studies with biliary injury (with or without SCN) exceeded 3× upper limit of normal average control values, a lack of ALP sensitivity is demonstrated for detecting BD injury. Total bilirubin was increased over control values, in at least one dose group in 12 of the liver injury studies in which it was measured and in one specificity study with muscle and GI damage. Five of seven BD injury studies where total bilirubin was measured had an increase, but these increases were not specific to biliary injury as seven of the studies with hepatocellular injury also had increases.
Individual animals from each study were partitioned into specific categories based on the observed histopathology findings, including controls, treated with no injury, liver findings of lesser concern (i.e., hypertrophy), hepatocellular injury terms, biliary injury terms, or terms of injury in kidney, muscle, and/ or GI organs (Table 3 ). The number of samples in each category Notes.
For each study, dose levels, necropsy days, and histomorphological outcomes are listed. AST, ALP, and total bilirubin were not evaluated in this analysis of ARG1, GSTA, and HPD; however, they are serum markers of liver injury so studies with abnormal levels were noted. Data from eight studies with hepatocellular injury were used to fit a linear logistic model (Harrell, 2001) for each marker individually. The diagnostic score based on the models was used to estimate fold change associated with a 0.67 probability of liver injury. The average percent change per dose group over control cutoff for each analyte is as follows: ALT = 110, AST = 78, ALP = 33, and total bilirubin = 36 (see Supplementary table 1 for more details) . Red cells, substantial change at all doses and time points; pink cells, substantial change in at least one dose or time point; grey cells, no data collected. Navy blue, hepatocellular necrosis/degeneration; teal blue, biliary injury; light blue, hepatocellular vacuolation and hypertrophy; orange, nonliver injury. ANIT, α-naphthyl-isothiocyanate; NPAA, n-phenyl-anthranilic acid; TMPD, Wurster's Reagent or N,N,N′,N′-tetramethyl-p-phenylenediamine; mkd, milligrams/ kilograms/day. 8  TMPD  2  2  1  8  TMPD  4  2  5  8  TMPD  4  3  5  8  TMPD  6  2  5  8  TMPD  6  3  4  11  Monensin  20  8  7  25  Allylamine  50  8  4  25  Allylamine  75  4  3  31  Merck-M  75  5  3  31  Merck-M  750  2  1  33  Merck-D  15  8  2  33 Merck-D 5 3 1 GI 16 3
Merck-E 10 8 4 3
Merck-E 300 8 2 24
Merck-F 750 8 2 28
Merck-G Thioacetamide  100  3  4  12  Thioacetamide  200  3  4  12  Thioacetamide  50  3  5  13  Acetaminophen  2500  2  4  13  Acetaminophen  2500  4  4  13  Acetaminophen  5000  2  1  13  Acetaminophen  5000  4  3  16  Bromobenzene  300  2  5  16 Bromobenzene 750 Notes. Summary incidence of treatment-related findings by dose group and number of animals for each tissue and morphologic diagnosis. Specificity categories are on the left side of the table and sensitivity categories are shown on the right. Total number (∑) of samples is given in bold for each category with number (N) of animals in each dose group within the category listed below it. Study numbers are included because some compounds were tested in a second study. Hepatocellular changes were the most common class of morphological change observed in the liver. Hepatocellular necrosis and/or degeneration were observed in rats from nine studies, with a total of 76 animals testing positive. Animals without organ injury included vehicle-treated animals (Control), animals treated with a liver toxicant with no liver injury (Liver Active No Injury), and animals without liver injury treated with compounds that resulted in GI, kidney, or muscle injury (NonLiver Active No Injury). For samples with multiple organ injuries, liver was prioritization over the other organs. For samples with multiple liver injuries, hepatocellular necrosis and degeneration were given precedence. Although animals with both SCN and BD injury are given a separate class in some instances, SCN was given precedence. Both of these were given precedence over hepatocell ular vacuolation which, in turn, was given precedence over liver hypertrophy. ranged from 8 to 170. Samples in categories used to evaluate biomarker performance for specificity totaled 131 (excluding control and no injury) and for sensitivity totaled 167.
Detecting Hepatocellular Changes: Receiver Operator Characteristic Analysis and Logistic Regression
A cohort was formed initially using the rats in eight studies in which hepatocellular necrosis and/or degeneration was observed (Table 2) . This cohort was used to characterize the sensitivity of each biomarker for detecting hepatocellular changes. Receiver operator characteristic (ROC) analysis was performed on all studies within this cohort (Fig. 1) . Area under the curve (AUC) values of > 0.9 for all four analytes demonstrated similar overall performance of each biomarker in detecting hepatocellular necrosis and/or degeneration.
The results of logistic fits for each of the biomarkers individually and in combination with ALT are shown in Supplementary table 2. These models were used for several purposes. First, they support the ROC analysis showing strong performance for each biomarker to detect hepatocellular injury. Second, they provided a way to plot the biomarker response based on the probability of hepatocellular injury rather than fold change. For example, based on the models, the estimated fold change associated with a 67% probability of hepatocellular injury is 1.96 for ALT, but 2.61, 3.76, and 3.86 for HPD, ARG1, and GSTA, respectively. Third, for each sample, the diagnostic values generated by applying the logistic equations yield an assessment of the extent to which each biomarker provides evidence of hepatic necrosis/degeneration in that sample. The samples with hepatic injury allowed assessment of sensitivity, and samples without hepatic injury allowed assessment of specificity. By comparing the change in diagnostic values between the logistic models with ALT alone and the model with ALT and the biomarker, the amount of information added by the biomarker was evaluated. The small p values from the likelihood ratio test means the likelihood that the model is detecting real signal from the additional biomarkers that adds to the accuracy of diagnosing hepatocellular injury is higher. A model that includes each of the biomarkers with ALT shows better performance than a model with ALT alone.
Summary of Biomarker Concordance With Categories of Histopathology Outcomes
Scatter plots were generated for each study to evaluate biomarker performance over multiple doses and/or times. Figures 2A and 2B illustrate examples of a specificity study on the muscle toxicant TMPD and of a sensitivity study on a hepatotoxicant, thioacetamide. In the TMPD study, GSTA and ALT increased with increasing doses (2, 4, and 6 mg/kg/day) (GSTA on SD2, ALT on SD2 and SD3) relative to controls. ARG1 did not show an increase in any treated animal above the variance seen in the controls. For this muscle-specific toxicant, HPD appeared to have the best specificity; however, it should be kept in mind that with this fit-for-purpose assay, HPD levels are often below the level of quantification in controls and treated animals with no liver injury. Thioacetamide was administered at three separate doses (50, 100, 200 mkg/ kg/day) that all resulted in hepatocellular injury. All three novel biomarkers and ALT increased with increasing dose and severity of injury; however, the magnitude of change over controls in the lowest dose was greater for GSTA, ARG1, and HPD (5× to 16×) than was the fold change for ALT (2×). Even at the highest dose, all the animals showed a more robust response with ARG1 and HPD to liver injury than with GSTA or ALT.
Boxplots were used to depict biomarker performance for rats in specific categories based on histopathological changes (Figs. 3A-D). In each plot, the analyte values normalized to concurrent mean control were plotted for each class of histomorphological change observed. The categories themselves can be grouped into samples without changes (Controls, Liver Active No Injury, Nonliver Active No Injury), samples with liver findings of lesser concern, Hypertrophy, samples with changes in other organs (Kidney, Muscle, GI, or GI + Muscle), and samples with liver changes of greater concern, namely Necrosis and Degeneration (Hepatocellular, SCN, and BD) , and Vacuolation. The number of samples in each category is shown at the top of each graph. For each category, the median is shown as a line within each box and the box encloses the middle 50% of the data. Overlaid on the boxplots are lines marking the reference values 0.10, 0.33, 0.67, and 0.90 from the logistic regression equations in Supplementary table 2. The dashed line represents the 95% specificity cutoff from the ROC curve. Finally, individual animal data are plotted (Xs on graphs). As a summary for each histopathological category, medians above the 0.67 (y-axis) . The x-axis plots the dose and time (e.g., 2.02 = 2 mkd on study day 2). Plots for all other studies can be found in Supplementary fig. 1 .
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BAILEY ET AL. reference line could be considered as indicative of the marker having a positive response in samples from that category, medians below 0.33 as indicative of the marker having a low or no response, and medians between 0.33 and 0.67 as intermediate. Figure 3A shows that GSTA generally has a ratio of treated to controls (analyte:control) near 1 in samples which exhibit no injuries. Samples from rats with liver vacuolation or hypertrophy generally have GSTA ratios to control that are increased to the same degree, medians above the 0.67 threshold near the 95% confidence from the ROC analysis, thus decreasing this marker's specificity in detecting bona-fide liver injury as vacuolation is considered injury and hypertrophy is not. GSTA does not give a false signal of liver injury in studies with muscle injury (analyte:control median = 2) but was less specific when there was kidney, GI, or GI+muscle injury with median values within the logistic threshold region (0.33-0.67). Aside from detecting hepatocellular necrosis and/or degeneration well (median > 0.9 logistic threshold), GSTA detected SCN in most samples (median > 0.9 logistic threshold). It did not, however, appear to perform well at detecting BD necrosis or hyperplasia (Bile.Duct) but was able to detect BD damage when there was also SCN present (SCN+BD) (analyte:control median = 1 and 4, respectively). Figure 3B shows that median ARG1 ratios to control are similar and near 1 for all categories with no injuries. Interestingly, ARG1 showed a slightly higher medium ratio for hypertrophy than vacuolation with both falling between the 0.33 and 0.67 logistic thresholds. Median ratios for rats with kidney or muscle changes were near 1; however, there were rats in these groups with ARG1 increased to levels associated with liver changes. Rats with GI or GI + Muscle changes tended to have ARG1 medians in the intermediate logistic zone (0.33-0.67). Notes. Proportion improved = proportion with predicted injury in marker + ALT model closer to truth compared with ALT model; proportion worse = proportion with predicted injury in marker + ALT model less close to truth compared with ALT model; nri = proportion improved−proportion worse; p.nri = p value of null, nri = 0; improveSens = for positives, mean predicted value (ALT + marker model)−mean predicted value (ALT model); improveSpec = for negatives, mean predicted value (ALT model)−mean predicted value (ALT + marker model). Bolded values for "Proportion improved" >0.50 and for "p.nri" <0.50. FIG. 3 . Box/Dot plots of biomarker performance across 34 studies. n = total number of samples in each category. Individual data points of the ratio analyte:control for each category are represented by X's in the plots. The box encloses the middle 50% of the data, and the line in the box is the median. Grey lines: cutoffs from the linear logistic regression model-pr(Liver Damage) as described in Supplementary table 2 ARG1 showed good sensitivity in detecting hepatocellular injury including SCN with or without BD injury (median > 0.67 logistic threshold). It was modestly effective at detecting BD injury alone (median = 0.33-0.67).
NOVEL DRUG-INDUCED LIVER INJURY BIOMARKERS
HPD displayed a pattern of response that was more discrete than the other markers (Fig. 3C) . Decreased sensitivity of the HPD assay at low concentrations resulted in values below the LOQ for the vast majority of samples in the control and no injury categories. Although this may have hindered evaluation of specificity in the low range, overall HPD showed the greatest specificity for detecting liver injury in samples with hypertrophy, or injury to any other organ evaluated including GI with or without muscle injury. There were instances in which HPD was increased without meaningful changes in the liver (e.g., hypertrophy); however, these instances were uncommon. HPD was substantially increased in rats with hepatocellular injury including SCN (analyte:control median > 0.9 logistic threshold) and SCN + BD (0.33-0.67). Although some rats with BD changes alone had an increase in HPD, the median ratio with control was 1.
The performance of all three of these markers can be compared against that of ALT shown in Figure 3D . ALT showed poor specificity in the presence of hepatocellular hypertrophy, as well as GI and/or muscle injury (analyte:control median > 0.67 logistic threshold). Specificity in the presence of kidney toxicity was lower than that of the other organs (analyte:control median < 0.33). Vacuolation was associated with a modest increase but lower than that seen with hypertrophy (0.33-0.67), the same pattern seen with ARG1. Hepatocellular injury was detected by ALT with high sensitivity (analyte:control median > 0.9 logistic threshold) as was SCN (analyte:control median > 0.67 logistic threshold), whereas sensitivity to detect bile duct injury was in the same range as ARG1 (0.33-0.67) unless it was associated with SCN (analyte:control median > 0.9 logistic threshold).
Each biomarker was then evaluated to determine the correlation between the magnitude of response and severity of injury (Supplementary figs. 2A-D). Discussion of this analysis can be found in the legend of Supplementary fig. 2 .
To better visualize the relative performance of each biomarker, sensitivity and specificity estimates based on the 0.33 and 0.67 cutoffs derived from the logistic regression models are depicted in Figure 4 . On the left side of the display, sensitivity estimates for the categories of positive liver injury are shown. For each marker and category, sensitivity estimates are given for both a threshold of > 0.67 and a less stringent threshold of > 0.33. The right side of the display gives specificity estimates for a selected set of categories which are not positive for liver injury.
The first two displays in the sensitivity column show that for all liver injury terms combined or just hepatocellular (necrosis/degeneration) changes, the markers performed similarly to each other whether or not the regression cutoff was set at 0.33 or 0.67 (sensitivity = 0.7-0.9). ARG1 and ALT show greater sensitivity than GSTA or HPD at detecting SCN (sensitivity = 0.8-0.9) with logistic model threshold > 0.33. A similar difference was seen among the biomarkers in the diagnosis of BD injury, with ARG1 and ALT being more sensitive (sensitivity = 0.6-0.7) than HPD and GSTA (sensitivity = 0.4-0.5) with the less stringent cutoff of > 0.33. For samples without liver injury, HPD showed the best specificity with liver hypertrophy (specificity = 0.7) at the more stringent cutoff (< 0.33). For accurately diagnosing the absence of liver injury in the presence of kidney injury, both HPD and ALT were highly specific (specificity 0.8-1.0 at threshold < 0.33), ARG1 was moderately specific (0.6 at threshold < 0.33), whereas GSTA was not (specificity = 0.4 at threshold < 0.33). This may be due to the abundance of GSTA in the kidney (Table 1) . However, HPD is also present in the kidney and yet does not show the same lack of specificity. The lower right plots of Figure 4 display the greatest shortcoming of ALT, namely that it is not specific in the presence of GI or muscle changes (specificity = 0-0.2). It is important to note that studies with GI and muscle toxicity were selected for candidate biomarker evaluation because increased ALT levels are known to occur in these tissues following injury and increases were observed for these compounds. Although the ALT/AST ratio is a good diagnostic indicator of muscle injury, ALT increases are, nonetheless, not specific to liver injury. All three markers were shown to outperform ALT when tested in these extrahepatic injury samples, with HPD having the highest specificity at nearly 1.0 at the more stringent < 0.33 threshold.
A heat map of each biomarker by dose group helps visualize which types of histopathology categories are associated with the presence or absence of serum biomarker candidates and ALT (Supplementary fig. 3 ). Discussion of this analysis can be found in the legend of Supplementary fig. 3 .
Adding Value to ALT by Combining Biomarkers With a Logistic Regression Model
As mentioned above, to evaluate the information that each marker adds to the ALT, a logistic regression model pairing each marker in turn with ALT was fit using the hepatocellular cohort. The coefficients from these model fits are included at the bottom of Supplementary table 2. Table 4 investigates the extent to which each biomarker adds information for the other subgroups within the cohort. The primary metric for assessing performance in each group was as follows: The proportion of samples for which the diagnostic score (based on the logistic regression) of ALT with the marker improved as compared with the score of ALT alone. Improvement here means closer to 1 for samples with positive liver changes or closer to 0 for samples without positive liver findings. Table 4 gives the proportion of scores improved, the proportion of scores made worse, and net reclassification index (i.e., nri, difference between proportion improved and proportion worse) along with p values (p.nri) for the net reclassification index. The right most column of Table 4 gives the mean improvement of the diagnosis scores with the addition of the marker to ALT model, which is a measure of the magnitude of the improvement. The upper portion of Table 4 shows subsets of samples with positive liver morphological findings and the lower portion shows specificity subsets. The upper portion shows that adding any of the three markers to ALT increased the sensitivity to detect SCN; however, none of the p values were significant so this could be due to chance. ARG1 can add sensitivity to ALT alone for detecting biliary injury. The addition of HPD or GSTA to ALT reduced sensitivity to detect BD changes. Similarly, HPD combined with ALT reduces sensitivity for detecting vacuolation, whereas GSTA improves it. The lower portion of the table shows that all three markers add information to ALT that increases specificity to muscle and GI toxicants. HPD also adds information to ALT that increases specificity to liver hypertrophy. All three biomarkers reduce the false positive rate of ALT alone for control and treated samples with no histopathology.
DISCUSSION
Qualification of novel safety biomarkers is a complex process involving objective evaluation and determining performance against specific claims and context of use (Mattes et al., 2010; Warnock and Peck, 2010) . In order to support a fit-forpurpose claim, specific criteria were taken into consideration when selecting candidate novel biomarkers to improve diagnosis of drug-induced liver injury.
The first consideration was identifying the liabilities associated with the traditional biomarkers namely ALT, AST, ALP, and total bilirubin. Although AST, ALP, and total bilirubin were not directly compared with the three novel biomarkers in this evaluation, in general, AST responded in concert with ALT, and ALP was not sensitive or specific in that it was increased (> 3 upper limit of normal) in only two individual animals in seven studies with biliary injury and was increased in four studies with muscle injury. Total bilirubin was not routinely measured in this set of toxicity studies. When it was measured, it did not show sensitivity in studies with BD injury and was increased in animals with hepatocellular injury as well. Identifying the limitations of existing biomarkers provided clear benchmarks or claims for the candidates under consideration. Namely, these NOVEL DRUG-INDUCED LIVER INJURY BIOMARKERS claims include lack of specificity for hepatic injury, poor sensitivity to subtle liver injuries such as vacuolation, SCN, or low-grade biliary toxicity, and determining risk for toxicity in samples with slight increases in ALT without histomorphological changes.
Next, the relative abundance in liver versus other organs and the biological function of a candidate biomarker had to reflect leakage due to injury, response following injury, or impaired function . The existence of preclinical and clinical data showing association with liver injury was considered, the ability to detect the biomarker in sera/plasma was assessed, and finally, the availability of assays was determined. Applying these criteria, GSTA, ARG1, and HPD were selected for evaluation as biomarkers of liver injury that could potentially add value in terms of specificity and/or sensitivity.
Third, sample selection was critical to the candidate evaluation process. Each study was selected to assess a given use claim. The histopathological endpoints were categorized based on best practices agreed upon by the PSTC Hepatotoxicity Working Group. Within a study, histopathology is rarely, if ever, homogeneous for a single type of injury in every animal within a dose group or between dose groups. Therefore, predetermined rules on how to treat the various findings were established prior to data analysis. Vacuolation is often, but not always, found in studies with more severe liver injury and as such was considered a positive finding in the rule scheme. Conversely, hypertrophy is often seen alone and generally considered benign so was treated as a noninjury finding. A positive biomarker response in a sample with hypertrophy alone was therefore considered a false positive. Other rules could be followed such as excluding samples with vacuolation and hypertrophy alone from studies that had doses or time points with more severe findings. However, this strategy could potentially over estimate the performance of a novel biomarker.
Finally, appropriate statistical analyses to characterize performance were selected to determine whether the candidate biomarkers added value to established reference standards. Recommendations outlined in the FDA Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests (FDA-Guidance, 2007) were taken into consideration for the data analysis methods applied in this evaluation. ROC curves and logistic regression were employed to assess the biological performance of GSTA, ARG1, and HPD to predict histopathological outcomes in rodent toxicity studies. Although ROC analysis does provide reasonable summary statistics (e.g., AUC) of sensitivity and specificity across multiple analytes for a broad data set, it does not easily allow for the evaluation of an individual candidate's performance with respect to specific types of liver injury. Logistic regression models support the ROC analysis, provide a way to benchmark the markers based on probability of hepatocellular injury rather than fold change, and allow an assessment of the amount of information added by each biomarker to the ALT model alone. In this data set, ROC and logistic regression results showed comparable performance of each of the markers to detect hepatocellular injury.
For some of the studies, hepatocellular injury was regionally sublocalized as centrilobular or periportal. The observation that some of the markers were more sensitive to BD and periportal injury than others suggests that considering the markers together may have some value for localizing the region of injury. For instance, because ALT appears to be more sensitive to BD/periportal injury than HPD, a combination of these markers (e.g., HPD/ALT ratio) may be useful for discriminating between centrilobular and periportal injury if the injury is not too severe. The current sample size with hepatocellular necrosis in the periportal regions associated with BD injury was insufficient to determine whether any improved performance is due to the subregional localization or the specific type of injury that was observed (data not shown). Additional data from subregional analysis are needed to assess whether any of these candidates could enhance the ability of ALT to differentially diagnose such localized findings.
Although all three candidate biomarkers performed well in detecting hepatocellular necrosis/degeneration, none showed superior sensitivity over ALT alone in the set of toxicants evaluated. Combining any of the biomarkers with ALT did improve the diagnostic ability of ALT to detect SCN. ARG1 improved the sensitivity of ALT to detect biliary injury and GSTA combined with ALT increase the sensitivity to detect vacuolation. All three novel biomarkers increased with increasing severity of hepatocellular but not with increasing severity of BD injury. Because each of the markers had the most robust response to hepatocellular necrosis/degeneration, correlation with any grade injury to SCN or biliary hyperplasia was indistinguishable from a low-grade necrosis/degeneration response.
Transaminase increases can be due to extrahepatic tissue injury; therefore, a large number of specificity studies were included in this evaluation. In fact, studies were purposely selected based on known increases of ALT values in the absence of liver injury. Although GI and muscle injury often have an increased ALT signal, there is no evidence of an increase in ALT with kidney injury. Although HPD and GSTA are both abundant in the kidney, GSTA is the only liver injury candidate that showed a response in plasma to kidney toxicity in the absence of liver injury. Perhaps differential renal expression of GSTA and HPD accounts for the absence of HPD in the serum of samples with kidney injury. GSTA has, in fact, been evaluated as a urinary biomarker of kidney toxicity (Prozialeck et al., 2009) . All three biomarkers outperformed ALT in terms of specificity against GI and muscle injury in the absence of liver injury. Therefore, it was not surprising to find that each of the biomarkers improved specificity when combined with ALT in the presence of GI or muscle injury given their individual superior performance over ALT alone. HPD was the only candidate that when combined with ALT improved specificity in samples with liver hypertrophy.
In conclusion, GSTA, ARG1, and HPD were evaluated using a variety of studies to address both specificity and sensitivity of these markers, alone or in combination with ALT, for monitoring liver toxicity. Taken together, these biomarkers add value for the claim of specificity alone or in combination with ALT, reducing the false-positive rate of ALT seen in extrahepatic tissues or with liver changes of lesser concern. In addition, they enhance sensitivity for detecting SCN and in the case of ARG1, biliary injury. Further performance evaluation of these three novel biomarkers should include assessment of available preclinical studies that model transient ALT changes similar to what is observed in the clinic. The preclinical performance of these candidates warrants independent validation of the three assays and nomination of these safety biomarkers for global qualification.
